Why the study?
Are copeptin levels associated with microvascular dysfunction and infarct size in patients after STEMI?
Are copeptin levels associated with microvascular dysfunction and infarct size in patients after STEMI?
Persistently elevated copeptin at 24 hours in STEMI patients with CMD suggests arginine vasopressin may contribute to microvascular dysfunction, highlighting a potential novel therapeutic target.
Answers are grounded in this paper and cite their sources.
Elevated 24-hour copeptin in post-STEMI CMD may implicate vasopressin pathways; extends RCT biomarker data without infarct size linkage.
=0.011). Patients with microvascular obstruction on early CMR imaging showed a trend toward higher admission copeptin, which was not statistically significant. Copeptin levels were not associated with infarct size on either early or late CMR. Conclusions Patients with CMD after STEMI have persistently elevated copeptin at 24 hours, suggesting arginine vasopressin may contribute to microvascular dysfunction. Arginine vasopressin receptor antagonists may represent a novel therapeutic option in patients with STEMI and CMD.
No takes yet. Share an insight, caveat, or question.
Al‐Atta et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: